Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4337112 | 0.85 | HSPB1 (0.58) | LMNACA12CA1CA2CA7 | |
| SCHEMBL31504334 | 0.81 | MAOB (0.56) | LMNACA12CA1CA2CA7 | |
| SCHEMBL4337519 | 0.81 | MAOB (0.56) | LMNACA12CA1CA2CA7 | |
| SCHEMBL1401653 | 0.79 | SMN1; SMN2 (0.48) | LMNAHSPB1MAOBMAPTATM | |
| SCHEMBL26124874 | 0.77 | ADAMTS4 (0.52) | LMNACA12CA1CA2CA7 | |
| SCHEMBL31634187 | 0.77 | LMNA (0.54) | LMNACA12CA1CA2CA7 | |
| SCHEMBL4333136 | 0.75 | MAOB (0.53) | MAOBMAPT | |
| SCHEMBL28621039 | 0.74 | CA12 (0.76) | LMNACA12CA1CA2CA7 | |
| SCHEMBL1578614 | 0.74 | CA12 (0.66) | LMNACA12CA1CA2CA7 | |
| SCHEMBL20809471 | 0.74 | RAB9A (0.49) | LMNAMAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1511718-B1 | N-ACYLAMINOBENZENE DERVATIVES AS SELECTIVE MONOAMINE OXIDASE B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-05-06 | — | — | EP | disclosed |
| US-7053245-B2 | N-acylamino benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050283019-A1 | N-acylamino benzyl ether derivatives | JOLIDON SYNESE | 2005-12-22 | — | — | US | disclosed |
| EP-1511718-A1 | N-ACYLAMINOBENZENE DERVATIVES AS SELECTIVE MONOAMINE OXIDASE B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-09 | — | — | EP | disclosed |
| US-20040210079-A1 | N-acylamino benzyl ether derivatives | JOLIDON SYNESE | 2004-10-21 | — | — | US | disclosed |
| US-6762320-B2 | MONOAMINE OXIDASE B INHIBITORS; ALZHEIMER'S DISEASE, SENILE DEMENTIA | HOFFMAN-LA ROCHE INC. | 2004-07-13 | — | — | US | disclosed |
| US-20030232883-A1 | N-acylamino benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003099763-A1 | N-ACYLAMINOBENZENE DERVATIVES AS SELECTIVE MONOAMINE OXIDASE B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232883-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, AOC2 | LMNA 1977/4885CA12 3264/4885CA1 2195/4885 |
| US-20040210079-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, CBR1 | LMNA 1814/4885CA12 3340/4885CA1 2387/4885 |
| US-20050283019-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, AOC2 | LMNA 2132/4885CA12 3918/4885CA1 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.